An unfavorable ruling by a judge has scuttled an agreement in which Eli Lilly would have capped insulin prices and paid $13.5 million to resolve claims that it had inflated the drug's cost.

Lawyers for a proposed nationwide class of individuals, who paid for Lilly's Humalog injection and other insulin drugs, said in a filing in Newark, N.J. federal court that they and Lilly had decided not to go forward seeking approval for the deal.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee Participation
Employee-Paid
Employer-Paid